Olmesartanmedoxomil/ Hydrochloorthiazide Sandoz (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartanmedoxomil/ Hydrochloorthiazide Sandoz, is an Angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension, often in combination with a thiazide diuretic, and is prescribed for adult patients requiring blood pressure control.

GNH USA supplies Olmesartanmedoxomil/ Hydrochloorthiazide Sandoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxil / Hydrochlorothiazide is an antihypertensive medication that acts on the renin‑angiotensin system and renal sodium handling.

- Primary (essential) hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Secondary hypertension: provides effective blood pressure control when hypertension is due to identifiable causes. - Hypertension with fluid retention: combines vasodilation with diuresis to manage elevated blood pressure and excess extracellular fluid.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Headache: mild to moderate intensity. - Fatigue: feeling of tiredness or reduced energy. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Mild gastrointestinal discomfort: occasional nausea or abdominal pain.

Serious or Rare Side Effects: - Severe dehydration: marked fluid loss requiring medical attention. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: dangerously high potassium levels, especially with other potassium‑sparing agents. - Allergic reactions: rash, itching, or hives. - Angioedema: swelling of face, lips, tongue, or throat. - Severe electrolyte disturbances: significant hyponatremia or hypokalemia.

Patients should be monitored for blood pressure response and renal function while on therapy.

- Blood pressure monitoring: ensure target levels are achieved without excessive hypotension. - Renal function assessment: check serum creatinine and eGFR before and during treatment. - Electrolyte surveillance: periodic measurement of potassium and sodium. - Pregnancy caution: contraindicated in pregnancy (Category D) due to fetal risk. - Concomitant drug review: avoid combining with other potent diuretics or potassium‑sparing agents without supervision. - Store at room temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil / Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Aliskiren: combined use can increase risk of renal impairment and hyperkalemia. - Lithium: thiazide component may raise lithium levels, leading to toxicity. - NSAIDs: may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: concurrent use raises risk of hyperkalemia and renal dysfunction. - Potassium‑sparing diuretics: increase risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood pressure lowering effect. - Calcium channel blockers: may enhance antihypertensive response. - Antidiabetic agents: diuretic may affect glucose control. - Antidepressants (SSRIs): potential for increased serum sodium loss. - Antimicrobials (e.g., ciprofloxacin): may affect renal clearance of the ARB.